{‘She possesses little expertise’: this US medical establishment girds for Dr. Høeg's tenure at the Food and Drug Administration.

As the United States continues making historic changes to its immunization schedules, a particular individual appears somewhat surprisingly: Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccines throughout the pandemic and has zeroed in on possible fatalities after COVID-19 vaccination in her brief time at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Agency leaders were set to reveal sweeping changes to the pediatric vaccine schedule in December, aligning the US with Denmark’s national calendar, according to reports – a major change that would place the US at odds with a large portion of the international standard with insufficient data for benefit. The announcement has been pushed back until the coming year.

Rather than the top vaccines chief, Høeg is set to address the audience at the event. She was recently named interim head of the FDA’s CDER, the fifth individual to head the division this year.

A New Direction at the FDA

The acting appointment might represent a strengthened alliance between the drug and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for ending specific pediatric immunization guidelines in the US in order to be more in line with the Danish model, a society with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – traditionally the purview of Dr. Prasad, director of the FDA’s CBER – rather than pharmaceutical oversight.

Concerns Over Background

Høeg has no apparent experience in medication creation, approval processes or management, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in running a large organization. She lacks background in pharmaceutical oversight.”

Previous heads of CBER would “be deeply familiar with legal statutes and the underlying principles of medication creation”, said a former acting FDA commissioner. “Objectively, she lacks the type of experience that previous people who ran the center have had.”

The drug center has an vast range of responsibilities at the agency, the former commissioner pointed out.

“Everybody just focuses on the novel medication approvals, but the off-patent medication office approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those have to be looked after,” Dr. Woodcock said. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a substantial administrative component to the position, which manages more than 5,000 staff members. “It is a massive administrative position, if you perform it correctly,” Woodcock added.

Agency Reaction and Contentious Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a representative said that the “inquiries stem from incorrect assumptions”.

“Her resume matches the responsibilities of her job,” the representative stated, noting the period Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial expedited medication authorization process that reportedly troubled her predecessors. “How are these drugs being chosen for this fast-track system? Who takes the calls?” Dr. Howard said. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards laxer oversight of most medications, except for immunizations.”

Established Track Record on Vaccines

Regarding immunizations, Høeg has a more documented, if troubling, history, some experts observe. She published a research paper using unconfirmed crowd-sourced reports to determine the rate of myocarditis following COVID-19 immunization. She counseled the Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccines are riskier than they are.

Part of her “desired changes” for the incoming administration encompassed altering rules for recently developed shots and ending “unnecessary” immunizations, she said following the vote on a online show. At the agency, Dr. Høeg has according to sources floated the idea of barring young men from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who begins with her conclusions and tailors the evidence to fit the data in a extremely deceptive, untruthful way,” Howard said.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow skeptics, {like|